Endothelin-1 levels and renal function in newborns of various gestational ages

What Was Tested

This observational study looks at Endothelin-1.

The study objectives were to determine whether uET-1 levels correlate with renal function parameters and/or fetal growth restriction, and if uET-1 is a potential neonatal AKI biomarker.

Why It Was Studied

Endothelin-1 (ET-1) has been implicated in renal pathogenesis, and elevated urinary ET-1 (uET-1) levels may correlate with progression of renal dysfunction.

Who Took Part

PubMed tags the participants as both men and women.

Sixty-three neonates were enrolled and divided into gestational age (GA) groups by weeks: 1) (24-30 6/7; n = 24); 2) (31-36 6/7; n = 26); and 3) (37-42; n = 13).

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Endothelin-1 study would be practical.

Additional preterm subgroups for fetal growth restriction analysis included: 1) Appropriate for GA (AGA; n = 40), and 2) Small for GA (SGA; n = 10).

ET-1 levels, measured using enzyme linked immunosorbent assay, were collected at birth (cord blood) and 24 h ( ± 4) of life (blood/urine).

What Was Measured

Endothelin-1 (ET-1) has been implicated in renal pathogenesis, and elevated urinary ET-1 (uET-1) levels may correlate with progression of renal dysfunction.

Topics PubMed links to this paper include Acute Kidney Injury, Biomarkers, Birth Weight, Creatinine, Endothelin-1, Enzyme-Linked Immunosorbent Assay and Fetal Blood.

The authors tagged it with the keywords ET-1, Endothelin 1, newborn and renal function.

What This Means in Plain Language

The paper is a pilot study of Endothelin-1.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Journal of neonatal-perinatal medicine), a journal based in United States.

More context: the Endothelin-1 compound page, all human trials.